Vaccine for clostridium botulinum neurotoxin
AssigneeOphidian Pharmaceuticals, Inc.
InventorJames A. Williams
Life of this patent
Estimating the term…
Abstract
The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
Claims10
A soluble fusion protein comprising a non-toxin protein sequence and a portion of the Clostridium botulinum type A toxin, said portion of the Clostridium botulinum type A toxin comprising a portion of the sequence of SEQ ID NO:28.
A host cell containing a recombinant expression vector, said vector encoding a protein comprising at least a portion of a Clostridium botulinum type A toxin protein sequence of SEQ ID NO:28, and wherein said host cell is capable of expressing said protein as a soluble protein in said host cell at a level greater than or equal to 0.75% of the total cellular protein.
A soluble fusion protein, comprising at least a portion of Clostridium botulinum C fragment linked to a poly-histidine tag.
Dependencies are inferred from the claim text.